ABLIM1

Across TCGA pan-cancer cohorts, ABLIM1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ABLIM1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ABLIM1 RNA is repressed in tumor relative to normal tissue. In most cancer types ABLIM1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and BLCA are the cancer types where ABLIM1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABLIM1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	III,IV	−1.086	<.001	10	view →
KIRC	Male	III,IV	−0.933	<.001	10	view →
BLCA	All	All	−1.228	<.001	9	view →
LIHC	Male	II,III,IV	+1.211	<.001	9	view →
HNSC	All	All	−0.658	<.001	8	view →
KICH	Male	All	−1.961	<.001	7	view →
LUAD	Female	II,III,IV	−1.335	<.001	7	view →
BRCA	All	III,IV	−1.486	<.001	6	view →
CHOL	All	All	+2.324	<.001	5	view →
LUSC	All	All	−0.602	<.001	5	view →
UCEC	All	All	−1.350	<.001	4	view →
PRAD	All	All	−0.598	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ABLIM1–THCA

Open the THCA breakdown →